Evidence map›Paper›PMID 27846346›Full record

ArticleBritish journal of pharmacology2017

Xenobiotic-metabolizing enzymes in Bacillus anthracis: molecular and functional analysis of a truncated arylamine N-acetyltransferase isozyme.

Xavier Kubiak, Romain Duval, Benjamin Pluvinage, Alain F Chaffotte, Jean-Marie Dupret, Fernando Rodrigues-Lima

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Comparative Investigation of 15 Xenobiotic-MetabolizingApplied and environmental microbiology · 2021
    Article
  3. [Expression of MIER3 in colorectal cancer and bioinformatic analysis of MIER3- interacting proteins].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Xavier KubiakMicalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.
Romain DuvalSorbonne Paris Cité, Univ Paris Diderot, Unité BFA, CNRS UMR 8251, Paris, France.
Benjamin PluvinageBiochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Alain F ChaffotteUnité de Résonance Magnétique Nucléaire des Biomolécules, Institut Pasteur, Paris, France.
Jean-Marie DupretSorbonne Paris Cité, Univ Paris Diderot, Unité BFA, CNRS UMR 8251, Paris, France.
Fernando Rodrigues-LimaSorbonne Paris Cité, Univ Paris Diderot, Unité BFA, CNRS UMR 8251, Paris, France.
Délégation Paris 7 · FRInstitut Pasteur · FRMicrobiologie de l’alimentation au service de la santé · FRUniversité Paris Cité · FRUniversity of Victoria · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe arylamine N-acetyltransferases (NATs) are xenobiotic-metabolizing enzymes that play an important role in the detoxification and/or bioactivation of arylamine drugs and xenobiotics. In bacteria, NATs may contribute to the resistance against antibiotics such as isoniazid or sulfamides through their acetylation, which makes this enzyme family a possible drug target. Bacillus anthracis, a bacterial species of clinical significance, expresses three NAT isozymes with distinct structural and enzymatic properties, including an inactive isozyme ((BACAN)NAT3). (BACAN)NAT3 features both a non-canonical Glu residue in its catalytic triad and a truncated C-terminus domain. However, the role these unusual characteristics play in the lack of activity of the (BACAN)NAT3 isozyme remains unclear. EXPERIMENTAL APPROACH: Protein engineering, recombinant expression, enzymatic analyses with aromatic amine substrates and phylogenetic analysis approaches were conducted. KEY

resultsThe deletion of guanine 580 (G580) in the nat3 gene was shown to be responsible for the expression of a truncated (BACAN)NAT3 isozyme. Artificial re-introduction of G580 in the nat3 gene led to a functional enzyme able to acetylate several arylamine drugs displaying structural characteristics comparable with its functional Bacillus cereus homologue ((BACCR)NAT3). Phylogenetic analysis of the nat3 gene in the B. cereus group further indicated that nat3 may constitute a pseudogene of the B. anthracis species. CONCLUSION AND IMPLICATIONS: The existence of NATs with distinct properties and evolution in Bacillus species may account for their adaptation to their diverse chemical environments. A better understanding of these isozymes is of importance for their possible use as drug targets. LINKED ARTICLES: This article is part of a themed section on Drug Metabolism and Antibiotic Resistance in Micro-organisms. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.14/issuetoc.

Indexed as

AminesArylamine N-AcetyltransferaseBacillus anthracisCircular DichroismCloning, MolecularIsoenzymesKineticsPhylogenyProtein EngineeringRecombinant ProteinsAminesArylamine N-AcetyltransferaseIsoenzymesRecombinant Proteins

Identifiers

PMID27846346
PMCPMC5481644
OpenAlexW2554207773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.